Orencia (Abatacept)

Orencia (abatacept) is a selective T-cell costimulation modulator, available as a lyophilized powder for intravenous (IV) administration in single-use vials of 250 mg and as a solution for subcutaneous (SC) administration in single-use syringes of 50, 75, and 125 mg or in autoinjectors of 125 mg/mL.for the treatment of:

• adult patients with moderately to severely active rheumatoid arthritis (RA).
  
• patients aged 2 ye
  
• ars and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA).
  
• adult patients with active psoriatic arthritis (PsA).
  
• prophylaxis of acute graft versus host disease (aGVHD), along with a calcineurin inhibitor and methotrexate, in adults and pediatric patients aged 2 years and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor.
  

Limitations of Use: Concomitant use of Orencia (abatacept) with other immunosuppressives [e.g., Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDS)] is not recommended.

Recommended Dosage: 

Intravenous Use for Adult RA and Adult PsA:  In adults, abatacept may be given intravenously (at weeks 0, 2, 4, and then every 4 weeks) in doses based upon body weight ranging from 500 mg to 1000 mg. 

Subcutaneous Use for Adult RA: Before the first subcutaneous dose, administer an optional loading dose as a single intravenous infusion as per the body weight categories above. Administer 125 mg by subcutaneous injection once weekly (within a day of the intravenous infusion if infusion is given). Patients switching from intravenous use to subcutaneous use, administer the first subcutaneous dose instead of the next scheduled intravenous dose.

Intravenous Use for pJIA in Pediatric Patients ≥6 Years Old: Pediatric patients weighing <75 kg administer 10 mg/kg intravenously and those weighing ≥75 kg administer the adult intravenous dosing regimen (not to exceed a maximum dose of 1,000 mg), as a 30-minute infusion. Subsequently, administer infusions at 2 and 4 weeks and every 4 weeks thereafter. 

Subcutaneous Use for pJIA in Pediatric Patients ≥2 Years Old: Administer subcutaneously without an intravenous loading dose. For pediatric patients body weight of 10 kg to less than 25 kg, administer 50 mg. For pediatric patients body weight of 25 kg to less than 50 kg (once weekly), administer 87.5 mg (once weekly). For pediatric patients body weight of 50 kg or more, administer 125 mg (once weekly).

Subcutaneous Use for Adult PsA: Administer 125 mg by subcutaneous injection once weekly without an intravenous loading dose. Patients switching from intravenous use to subcutaneous use, administer first subcutaneous dose instead of next scheduled intravenous dose. 

Intravenous Use for prophylaxis of aGVHD: For patients aged 6 years and older, administer at a 10 mg per kg dose (maximum dose 1,000 mg) as a 60-minute infusion on the day before transplantation, followed by a dose on Day 5, 14, and 28 after transplant. For patients aged 2 to less than 6 years, administer a 15 mg/kg dose as a 60­ minute infusion on the day before transplantation, followed by a 12 mg/kg dose as a 60-minute infusion on Days 5, 14, and 28 after transplant.

• Concurrent treatment with Orencia injection and a TNF antagonist is not recommended. While transitioning from TNF antagonist therapy to Orencia therapy, patients should be monitored for signs of infection. Additionally, concomitant use of this drug with other biologic RA/PsA therapy or JAK inhibitors is not recommended. 
  
• Serious infections, including sepsis and pneumonia, may occur in patients receiving Abatacept. Clinicians should exercise caution while using it in patients with a history of recurrent infections, underlying conditions that may predispose them to infections, or chronic, latent, or localized infections. Before initiating treatment, patients need to be screened for latent TB infection with a tuberculin skin test.
  
• Before initiating treatment with Abatacept in pediatric and adult patients, update vaccinations as per current vaccination guidelines. Live vaccines should not be administered concurrently with this treatment or within three months after discontinuation.
  
• Cytomegalovirus (CMV) invasive disease may occur in patients who received Orencia. Monitor them for CMV infection or reactivation for six months post-transplant regardless of the results of donor and recipient pre-transplant Cytomegalovirus (CMV) serology. Consider prophylaxis for CMV infection or reactivation.

What documents are required to import ORENCIA to India?

ORENCIA (abatacept) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

Is ORENCIA available in India?

ORENCIA (abatacept injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Orencia in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

ORENCIA can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of ORENCIA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Orencia injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the ORENCIA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Orencia®?

Abatacept is a Generic Name for the trade name drug Orencia®.

What is the Manufacturer’s Name of Orencia®?

Orencia® is manufactured by Bristol-Myers Squibb.

Is Orencia® approved by the FDA?

Yes, Orencia® is approved by the FDA. Date of first/initial approval: December 23, 2005.

What is the dosage and form of Orencia® supplied?

Orencia® is supplied as a lyophilized powder for intravenous (IV) administration in single-use vials of 250 mg and as a solution for subcutaneous (SC) administration in single-use syringes of 50 mg, 75 mg, and 125 mg or in autoinjectors of 125 mg/mL.

What are the most common side effects of Orencia®? 

The most common side effects of Orencia® are infusion reactions of chills, fever and hypertension and nonspecific symptoms of headache, nausea, dizziness, nasopharyngitis, back and body pain, and rash.

How much does Orencia® cost in India?

The cost of Orencia in India can vary. To procure this selective T cell costimulation modulator legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Orencia®?

Refrigerate Orencia lyophilized powder (supplied in a vial), and solution (supplied in a prefilled syringe or ClickJect autoinjector) at 2°C to 8°C (36°F to 46°F). Protect from light by storing in the original package until the time of use. Never allow the prefilled syringe or autoinjector to freeze.  

Is it safe to buy Orencia® online in India?

Yes, one can buy Orencia online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Orencia injections through legal channels.